| 32.48 0 (0%) | 03-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 37.94 | 1-year : | 44.32 |
| Resists | First : | 32.49 | Second : | 37.94 |
| Pivot price | 32.41 |
|||
| Supports | First : | 32.27 |
Second : | 32.13 |
| MAs | MA(5) : | 32.47 |
MA(20) : | 32.37 |
| MA(100) : | 24.56 |
MA(250) : | 16.81 |
|
| MACD | MACD : | 0.8  |
Signal : | 1.1 |
| %K %D | K(14,3) : | 96.8 |
D(3) : | 96.5 |
| RSI | RSI(14): 80.9 | |||
| 52-week | High : | 32.49 | Low : | 7.26 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CBAY ] has closed below upper band by 30.1%. Bollinger Bands are 92.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 32.51 - 32.67 | 32.67 - 32.8 |
| Low: | 32.09 - 32.28 | 32.28 - 32.44 |
| Close: | 32.2 - 32.49 | 32.49 - 32.74 |
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Wed, 17 Apr 2024
CymaBay Therapeutics Inc. (CBAY) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Lifestyle UK
Fri, 22 Mar 2024
CymaBay Therapeutics: Major Acquisition and Leadership Overhaul - TipRanks.com - TipRanks
Wed, 28 Feb 2024
CymaBay Therapeutics Inc. (CBAY) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Fri, 16 Feb 2024
CYMABAY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC ... - Business Wire
Mon, 12 Feb 2024
CymaBay Therapeutics, ContextLogic, Snap And Other Big Stocks Moving Higher On Monday - Markets Insider
Mon, 12 Feb 2024
Gilead Sciences Expands Liver Portfolio With Acquisition of CymaBay Therapeutics - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 115 (M) |
| Held by Insiders | 9.664e+007 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 9,300 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.01e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -74 % |
| Return on Assets (ttm) | 557.9 % |
| Return on Equity (ttm) | -22.1 % |
| Qtrly Rev. Growth | 3.107e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -200.54 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -73 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.17 |
| Price to Cash Flow | 4.04 |
| Dividend | 0 |
| Forward Dividend | 5.85e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|